Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Chen, Lu; Qi, Huijie; Zhang, Liudi; Li, Haixia; Shao, Jie; Chen, Haifei; Zhong, Ming; Shi, Xiaojin; Ye, Ting; Li, Qunyi

doi:10.1186/s12885-018-4951-z

Cited by 23 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, both the SNPs revealed the same trend on the UCC, indicating the homogeneous effects of FGFR4 SNPs on the progression and prognosis of UCC. In previous studies, the SNP rs2011077 has been found to be related to the occurrence of prostate cancer, and SNP rs1966265 influences the therapeutic effect in breast cancer [43,44]. Combined with the current study, these SNPs of FGFR4 may influence a broad spectrum of malignant neoplasm, which needs further investigation.…”

Section: Discussionsupporting

confidence: 58%

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Tsay

Lee

et al. 2019

IJERPH

View full text Add to dashboard Cite

Fibroblast growth factor receptor 4 (FGFR4) plays a prominent role in cell proliferation and cancer progression. This study explored the effect of FGFR4 single-nucleotide polymorphisms (SNPs) on the clinicopathological characteristics of urothelial cell carcinoma (UCC). This study was conducted to survey the possible correlation of the polymorphism of FGFR4 to the risk and clinicopathologic characteristics of UCC. Four loci of FGFR4 (rs2011077 T > C, rs351855 G > A, rs7708357 G>A, and rs1966265 A > G) were genotyped via the TaqMan allelic discrimination approach in 428 UCC cases and 856 controls. The results indicated that UCC subjects who carried the SNP rs2011077 TC+CC genotypes were significantly related to a higher tumor stage (odds ratio (OR): 1.751, 95% confidence interval (CI): 1.078–2.846), primary tumor size (OR: 1.637, 95% CI: 1.006–2.662), and histopathologic grading (OR: 1.919, 95% CI: 1.049–3.511). Moreover, the SNP rs1966265 AG+GG genotypes were prominently related to a higher tumor stage (OR: 1.769, 95% CI: 1.082–2.891), primary tumor size (OR: 1.654, 95% CI: 1.011–2.706), and histopathologic grading (OR: 2.006, 95% CI: 1.096–3.674) compared to individuals with AA homozygotes. In conclusion, our data reveal association of FGFR4 polymorphisms with UCC clinicopathologic characteristics. FGFR4 polymorphisms may serve as a marker or therapeutic target in UCC development.

show abstract

Section: Discussionsupporting

confidence: 58%

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Tsay

Lee

et al. 2019

IJERPH

View full text Add to dashboard Cite

show abstract

“…Conversely, an FGFR1-associated SNP (rs17182023) has been linked to a low FGFR1 protein expression and a reduced breast cancer risk [ 65 ]. Certain genetic variants, such as FGFR4 rs1966265 and FGFR2 rs2981578, have also been involved in the outcome of breast cancer patients treated with chemotherapeutic agents [ 66 ]. Overall, the aforementioned findings are not strong enough to suggest that these SNPs may be considered as a therapeutic target in breast cancer patients.…”

Section: Fgfr Genetic Alterations In Breast Cancermentioning

confidence: 99%

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

Santolla

Maggiolini

2020

Cancers

View full text Add to dashboard Cite

One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer. Here, we have recapitulated previous studies dealing with FGFR molecular aberrations, such as the gene amplification, point mutations, and chromosomal translocations that occur in breast cancer. Furthermore, alterations in the FGF/FGFR signaling across the different subtypes of breast cancer have been described. Next, we discussed the functional interplay between the FGF/FGFR axis and important components of the breast tumor microenvironment. Lastly, we pointed out the therapeutic usefulness of FGF/FGFR inhibitors, as revealed by preclinical and clinical models of breast cancer.

show abstract

“…FGFR4 rs1966265 changes chemotherapy response in breast cancer [ 62 ], higher risk of oral squamous cell carcinoma susceptibility [ 31 ], initiation of cervical cancer (Taiwanese women) [ 19 ], and higher risk of breast cancer in Chinese women of Heilongjiang province [ 16 ]. FGFR4 rs2011077 TC+CC polymorphism is associated with higher tumor stage, tumor size, and grading in urothelial cell carcinoma [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

et al. 2020

View full text Add to dashboard Cite

Fibroblast growth factor receptor 4 (FGFR4) is a cell surface receptor tyrosine kinases for FGFs. Several studies have focused on the association between FGFR4 polymorphisms and cancer development. This meta-analysis aimed to estimate the association between FGFR4 rs351855 (Gly388Arg), rs1966265 (Val10Ile), rs7708357, rs2011077, and rs376618 polymorphisms and cancer risk. Eligible studies were identified from electronic databases. All statistical analyses were achieved with the STATA 14.0 software. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) used to quantitatively estimate the association. Overall, no significant association was found between rs351855, rs2011077, and rs376618 polymorphism with the risk of overall cancer. The rs1966265 polymorphism significantly decreased the risk of cancer in recessive (OR=0.87, 95%CI=0.78-0.97, p=0.009, TT vs CT+CC) genetic model. Whereas the rs7708357 polymorphism was positively associated with cancer risk in dominant (OR=1.17, 95%CI=1.02-1.36, p=0.028) genetic model. Stratified analysis revealed that rs351855 variant significantly increased the risk of prostate cancer in heterozygous (OR=1.16, 95%CI=1.02-1.32, p=0.025 AG vs GG), dominant (OR=1.20, 95%CI=1.06-1.35, p=0.004, AG+AA vs GG), and allele (OR=1.22, 95%CI=1.06-1.41, p=0.005, A vs G) genetic models. In summary, the findings of this meta-analysis indicate that rs1966265, rs7708357 and rs351855 polymorphisms are correlated to cancer development. Further well-designed studies are necessary to draw more precise conclusions.

show abstract

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Cited by 23 publications

References 55 publications

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

Contact Info

Product

Resources

About